Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03207594
Other study ID # 102472
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 1, 2016
Est. completion date August 31, 2024

Study information

Verified date April 2024
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to improve cancer care and the delivery of cancer care. Researchers are interested in studying patient reported information and examining how different factors may impact cancer care.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 128
Est. completion date August 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Diagnosed with head/neck, lung, breast, prostate, gastrointestinal or gynecologic cancer - 21 years of age or older at time of study registration - Must have been referred to MUSC radiation oncology for treatment with curative radiation therapy - Must report current smoking defined as self-reporting smoking within the past 30 days using a structured intake questionnaire. Exclusion Criteria: - Patients with primary central nervous system malignancies will be excluded. - Patients that have other cancer disease types will be excluded due to either significant differences in standard radiation therapy approaches or rarity of disease required radiation. - Patients who are currently participating in the Medical University of South Carolina Hollings Cancer Center smoking cessation program - Patients who are unable to provide informed consent

Study Design


Intervention

Other:
Survey
Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
Saliva sample
Subjects will have saliva collected by a member of the study team using a cotton swab.
Smoking Status questions
Subjects will be asked to complete an assessment asking questions about his/her current smoking status

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with biochemically confirmed smoking cessation Biochemical confirmation will be determined by saliva samples 4 weeks after enrollment
Primary Number of patient who self-report smoking cessation Self-reported smoking cessation will be documented via smoking assessment questionnaire 4 weeks after enrollment
Secondary Average weekly smoke exposure reported cigarettes per day multiplied by the number of days smoked during radiation therapy (RT), summed over a period of time and normalized to yield an average weekly smoke exposure during RT. up to 62 weeks
Secondary Number of patients who participate in smoking cessation Completing one in-person visit where an individualized smoking cessation treatment plan is developed and implemented. up to 12 months after completion of RT.
Secondary Compliance with smoking cessation Two binary measure of compliance:
- completing at least three in person visits within 6 weeks of starting an individualized cessation treatment plan
- completing at least one in-person visit and at least two phone-based communications
up to 12 weeks after completion of RT
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2